|
US6365787B1
(en)
|
1994-09-30 |
2002-04-02 |
The Johns Hopkins University |
Compounds for the suppression of HIV TAT transactivation
|
|
ATE414149T1
(de)
*
|
1996-11-20 |
2008-11-15 |
Univ Yale |
Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
|
|
US7226730B1
(en)
*
|
1997-02-26 |
2007-06-05 |
The General Hospital Corporation |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
|
|
CA2282729A1
(en)
*
|
1997-02-26 |
1998-09-03 |
The General Hospital Corporation |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
|
|
US20030033621A1
(en)
*
|
1997-02-26 |
2003-02-13 |
De La Monte Suzanne |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
|
|
AU768834B2
(en)
*
|
1998-04-01 |
2004-01-08 |
Yale University |
A method for selectively modulating the interactions between survivin and tubulin
|
|
AU4990999A
(en)
*
|
1998-07-14 |
2000-02-07 |
Jenner Biotherapies, Inc. |
Survivin, and peptides thereof, as an anti-cancer vaccine
|
|
US6077709A
(en)
*
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
|
US6838283B2
(en)
|
1998-09-29 |
2005-01-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of survivin expression
|
|
US6335194B1
(en)
*
|
1998-09-29 |
2002-01-01 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of survivin expression
|
|
AU2003205017B2
(en)
*
|
1998-09-29 |
2005-12-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of survivin expression
|
|
US6773911B1
(en)
|
1998-11-23 |
2004-08-10 |
Amgen Canada Inc. |
Apoptosis-inducing factor
|
|
US6608108B2
(en)
*
|
1999-10-15 |
2003-08-19 |
Johns Hopkins University |
Method for treatment of tumors using nordihydroguaiaretic acid derivatives
|
|
DK1234031T3
(en)
|
1999-11-30 |
2017-07-03 |
Mayo Foundation |
B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
|
|
EP1237582B1
(en)
|
1999-12-10 |
2011-09-14 |
AntiCancer, Inc. |
Methods for introducing genes into mammalian subjects
|
|
US6509162B1
(en)
*
|
2000-02-29 |
2003-01-21 |
Yale University |
Methods for selectively modulating survivin apoptosis pathways
|
|
WO2002002622A2
(en)
*
|
2000-06-29 |
2002-01-10 |
The Salk Institute For Biological Studies |
Crystal structure of survivin
|
|
JP4368110B2
(ja)
*
|
2001-01-12 |
2009-11-18 |
エール ユニヴァーシティ |
癌患者の生物学的流体中のサバイビンの検出
|
|
US7776518B2
(en)
|
2001-01-12 |
2010-08-17 |
Yale University |
Detection of survivin in the biological fluids of cancer patients
|
|
DE10102722A1
(de)
*
|
2001-01-22 |
2002-08-14 |
Medinnova Ges Med Innovationen |
Verfahren und Testsystem zum Auffinden von Nervenzell-schützenden Substanzen
|
|
AU2003209297A1
(en)
*
|
2002-01-18 |
2003-09-02 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for preserving the viability of photoreceptor cells
|
|
US20040210035A1
(en)
*
|
2002-01-30 |
2004-10-21 |
Straten Eivind Per Thor |
Survivin-derived peptides and use thereof
|
|
US7892559B2
(en)
|
2002-01-30 |
2011-02-22 |
Survac Aps |
Survivin-derived peptides and use thereof
|
|
US7332580B2
(en)
*
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20040102395A1
(en)
*
|
2002-11-22 |
2004-05-27 |
Isis Pharmaceuticals Inc. |
Modulation of IAP-like expression
|
|
WO2004046386A1
(en)
|
2002-11-15 |
2004-06-03 |
Genomic Health, Inc. |
Gene expression profiling of egfr positive cancer
|
|
WO2004058293A1
(en)
*
|
2002-12-24 |
2004-07-15 |
Northern Therapeutics Inc. |
Methods of diagnosing, preventing, and treating early onset of pulmonary hypertension
|
|
US20040231909A1
(en)
|
2003-01-15 |
2004-11-25 |
Tai-Yang Luh |
Motorized vehicle having forward and backward differential structure
|
|
ES2633389T3
(es)
*
|
2003-01-30 |
2017-09-21 |
Survac Aps |
Péptidos derivados de survivina y uso de los mismos
|
|
AU2004211955B2
(en)
*
|
2003-02-06 |
2009-05-14 |
Cedars-Sinai Medical Center |
Gene expression markers for response to EGFR inhibitor drugs
|
|
US7713738B2
(en)
|
2003-02-10 |
2010-05-11 |
Enzon Pharmaceuticals, Inc. |
Oligomeric compounds for the modulation of survivin expression
|
|
WO2004074518A1
(en)
*
|
2003-02-20 |
2004-09-02 |
Genomic Health, Inc. |
Use of intronic rna to measure gene expression
|
|
ES2345200T3
(es)
*
|
2003-03-24 |
2010-09-17 |
The Scripps Research Institute |
Vacunas de adn contra el crecimiento tumoral y procedimientos de utilizacion de las mismas.
|
|
AU2004248140A1
(en)
*
|
2003-05-30 |
2004-12-23 |
Cedars-Sinai Medical Center |
Gene expression markers for response to EGFR inhibitor drugs
|
|
JP4579911B2
(ja)
|
2003-06-03 |
2010-11-10 |
アイシス・ファーマシューティカルズ・インコーポレイテッド |
スルビビン発現の調節
|
|
HUE050365T2
(hu)
|
2003-06-24 |
2022-09-28 |
Genomic Health Inc |
Rákkiújulás valószínûségének elõrejelzése
|
|
AU2004258085B2
(en)
*
|
2003-07-10 |
2010-05-27 |
Genomic Health, Inc. |
Expression profile algorithm and test for cancer prognosis
|
|
CA2542656A1
(en)
*
|
2003-10-16 |
2005-05-06 |
Genomic Health, Inc. |
Qrt-pcr assay system for gene expression profiling
|
|
WO2005049073A2
(en)
|
2003-11-19 |
2005-06-02 |
Survac Aps |
Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
|
|
AU2004309396B2
(en)
*
|
2003-12-23 |
2010-05-13 |
Genomic Health, Inc. |
Universal amplification of fragmented RNA
|
|
ES2636470T3
(es)
*
|
2004-04-09 |
2017-10-05 |
Genomic Health, Inc. |
Marcadores de expresión génica para predecir la respuesta a la quimioterapia
|
|
JP2007530075A
(ja)
*
|
2004-04-23 |
2007-11-01 |
エグザジェン ダイアグノスティクス インコーポレイテッド |
乳がんの予後診断のための組成物および方法
|
|
US7342093B2
(en)
|
2004-07-23 |
2008-03-11 |
University Of Massachusetts |
Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
|
|
DK1810026T3
(en)
|
2004-10-06 |
2018-07-16 |
Mayo Found Medical Education & Res |
B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
|
|
JP4939425B2
(ja)
*
|
2004-11-05 |
2012-05-23 |
ジェノミック ヘルス， インコーポレイテッド |
乳癌の治療反応の予後および予測の分子指標
|
|
CA2585571C
(en)
*
|
2004-11-05 |
2020-01-21 |
Genomic Health, Inc. |
Predicting response to chemotherapy using gene expression markers
|
|
WO2006050732A2
(en)
|
2004-11-09 |
2006-05-18 |
Santaris Pharma A/S |
Lna oligonucleotides and the treatment of cancer
|
|
DE602005012137D1
(de)
*
|
2004-11-12 |
2009-02-12 |
Life Sciences Res Partners Vzw |
Verwendung von survivin zur behandlung von niereninsuffizienz
|
|
MX2007007624A
(es)
*
|
2004-12-22 |
2007-08-03 |
Gillette Co |
Reduccion del crecimiento del pelo con inhibidores de survivina.
|
|
ES2523172T3
(es)
|
2005-02-04 |
2014-11-21 |
Survac Aps |
Vacuna de péptido de survivina
|
|
US7803375B2
(en)
*
|
2005-02-23 |
2010-09-28 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for treating conditions of the eye
|
|
US20060276423A1
(en)
*
|
2005-04-18 |
2006-12-07 |
Rachel Altura |
Survivin-directed RNA interference-compositions and methods
|
|
JP5421590B2
(ja)
|
2005-05-18 |
2014-02-19 |
ノバルティス アーゲー |
自己免疫および／または炎症性成分を有する疾患の診断および治療のための方法
|
|
US7272013B1
(en)
*
|
2005-07-28 |
2007-09-18 |
American Megatrends, Inc. |
Interchangeable design support system
|
|
US7592330B2
(en)
*
|
2005-08-08 |
2009-09-22 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for preserving the viability of photoreceptor cells
|
|
US7812173B2
(en)
*
|
2005-08-23 |
2010-10-12 |
E.I. Du Pont De Nemours And Company |
Tetrahydro-1,8-dioxa-4a-aza-naphthalenes in coating applications
|
|
US20070049752A1
(en)
*
|
2005-08-23 |
2007-03-01 |
Drysdale Neville E |
Preparation of 2,6-dioxa-7-aza-bicyclo[2.2.2] octanes
|
|
US20070104689A1
(en)
*
|
2005-09-27 |
2007-05-10 |
Merck Patent Gmbh |
Compositions and methods for treating tumors presenting survivin antigens
|
|
WO2007082154A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and b7-h4 in cancer
|
|
WO2007082144A2
(en)
*
|
2006-01-05 |
2007-07-19 |
Mayo Foundation For Medical Education And Research |
B7-h1 and survivin in cancer
|
|
WO2007124361A2
(en)
*
|
2006-04-20 |
2007-11-01 |
Mayo Foundation For Medical Education And Research |
Soluble b7-h1
|
|
WO2008140493A2
(en)
*
|
2006-11-21 |
2008-11-20 |
The Regents Of The University Of Californina |
Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
|
|
US8002827B2
(en)
|
2007-04-24 |
2011-08-23 |
Abbott Medical Optics Inc. |
Systems and methods for ocular measurements
|
|
US9216080B2
(en)
|
2007-08-27 |
2015-12-22 |
Amo Groningen B.V. |
Toric lens with decreased sensitivity to cylinder power and rotation and method of using the same
|
|
US8974526B2
(en)
*
|
2007-08-27 |
2015-03-10 |
Amo Groningen B.V. |
Multizonal lens with extended depth of focus
|
|
JP2011501731A
(ja)
*
|
2007-09-10 |
2011-01-13 |
ユニバーシティ オブ マサチューセッツ |
ミトコンドリア標的化抗腫瘍剤
|
|
ATE523810T1
(de)
|
2008-02-15 |
2011-09-15 |
Amo Regional Holdings |
System, brillenglas und verfahren zur erweiterung der fokustiefe
|
|
US8439498B2
(en)
|
2008-02-21 |
2013-05-14 |
Abbott Medical Optics Inc. |
Toric intraocular lens with modified power characteristics
|
|
WO2009111315A2
(en)
*
|
2008-02-29 |
2009-09-11 |
Mayo Foundation For Medical Education And Research |
Methods for reducing granulomatous inflammation
|
|
KR101648146B1
(ko)
|
2008-03-31 |
2016-08-16 |
텔라 가부시키가이샤 |
Ｍｈｃ 클래스 ⅱ 분자에 제시되는 서바이빈의 부분 펩타이드 및 그의 용도
|
|
US8862447B2
(en)
|
2010-04-30 |
2014-10-14 |
Amo Groningen B.V. |
Apparatus, system and method for predictive modeling to design, evaluate and optimize ophthalmic lenses
|
|
CA2784782C
(en)
|
2009-12-18 |
2018-02-27 |
Hendrik A. Weeber |
Limited echelette lens, systems and methods
|
|
WO2011133964A2
(en)
|
2010-04-23 |
2011-10-27 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
|
|
WO2012061045A2
(en)
|
2010-11-01 |
2012-05-10 |
Massachusetts Eye And Ear Infirmary |
Methods and compositions for preserving retinal ganglion cells
|
|
EP3330776A1
(en)
|
2010-12-01 |
2018-06-06 |
AMO Groningen B.V. |
A multifocal lens having an optical add power progression, and a system and method of providing same
|
|
EP2773341A2
(en)
|
2011-10-21 |
2014-09-10 |
Massachusetts Eye & Ear Infirmary |
Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
|
|
EP2928413B1
(en)
|
2012-12-04 |
2019-08-14 |
AMO Groningen B.V. |
Lenses systems and methods for providing binocular customized treatments to correct presbyopia
|
|
US9302005B2
(en)
|
2013-03-14 |
2016-04-05 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
CA2908042C
(en)
|
2013-03-27 |
2023-01-31 |
Immunovaccine Technologies Inc. |
Method for improving the efficacy of a survivin vaccine in the treatment of cancer
|
|
ES2714708T3
(es)
|
2013-10-01 |
2019-05-29 |
Mayo Found Medical Education & Res |
Procedimientos para el tratamiento de cáncer en pacientes con niveles elevados de Bim
|
|
CN105873941A
(zh)
*
|
2013-12-16 |
2016-08-17 |
默克专利有限公司 |
生存素导向的癌症疫苗治疗
|
|
US10302653B2
(en)
|
2014-05-22 |
2019-05-28 |
Mayo Foundation For Medical Education And Research |
Distinguishing antagonistic and agonistic anti B7-H1 antibodies
|
|
WO2016014148A1
(en)
|
2014-07-23 |
2016-01-28 |
Mayo Foundation For Medical Education And Research |
Targeting dna-pkcs and b7-h1 to treat cancer
|
|
EP3242883A4
(en)
|
2015-01-06 |
2018-10-17 |
ImmunoVaccine Technologies Inc. |
Lipid a mimics, methods of preparation, and uses thereof
|
|
EP3291842A4
(en)
|
2015-05-07 |
2019-01-23 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
SURVIVIN VACCINE VARIANT FOR THE TREATMENT OF CANCER
|
|
KR102773176B1
(ko)
*
|
2015-09-04 |
2025-02-27 |
헬스 리서치 인코포레이티드 |
암 치료용 안티-서비빈 항체
|
|
WO2017075045A2
(en)
|
2015-10-30 |
2017-05-04 |
Mayo Foundation For Medical Education And Research |
Antibodies to b7-h1
|
|
WO2017083963A1
(en)
|
2015-11-18 |
2017-05-26 |
Immunovaccine Technologies Inc. |
Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
|
|
EP3413840A1
(en)
|
2016-02-09 |
2018-12-19 |
AMO Groningen B.V. |
Progressive power intraocular lens, and methods of use and manufacture
|
|
US11123178B2
(en)
|
2016-03-23 |
2021-09-21 |
Johnson & Johnson Surgical Vision, Inc. |
Power calculator for an ophthalmic apparatus with corrective meridians having extended tolerance or operation band
|
|
AU2017238517B2
(en)
|
2016-03-23 |
2021-11-11 |
Johnson & Johnson Surgical Vision, Inc. |
Ophthalmic apparatus with corrective meridians having extended tolerance band
|
|
US11060087B2
(en)
*
|
2016-06-15 |
2021-07-13 |
The Regents Of The University Of California |
Synthetic promoters for high throughput screening and gene modulation
|
|
WO2018078439A2
(en)
|
2016-10-25 |
2018-05-03 |
Amo Groningen B.V. |
Realistic eye models to design and evaluate intraocular lenses for a large field of view
|
|
US10739227B2
(en)
|
2017-03-23 |
2020-08-11 |
Johnson & Johnson Surgical Vision, Inc. |
Methods and systems for measuring image quality
|
|
WO2019106067A1
(en)
|
2017-11-30 |
2019-06-06 |
Amo Groningen B.V. |
Intraocular lenses that improve post-surgical spectacle independent and methods of manufacturing thereof
|
|
FR3087448B1
(fr)
|
2018-10-23 |
2023-10-13 |
Pdc Line Pharma |
Lignee pdc modifiee pour secreter une cytokine
|
|
WO2020092839A1
(en)
|
2018-10-31 |
2020-05-07 |
Mayo Foundation For Medical Education And Research |
Methods and materials for treating cancer
|
|
EP3873540A4
(en)
|
2018-10-31 |
2022-07-27 |
Mayo Foundation for Medical Education and Research |
METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
|
|
US11886046B2
(en)
|
2019-12-30 |
2024-01-30 |
Amo Groningen B.V. |
Multi-region refractive lenses for vision treatment
|
|
EP4333685B1
(en)
|
2021-05-05 |
2026-01-14 |
AMO Groningen B.V. |
Ring halometer system and method for quantifying dysphotopsias
|
|
US12544218B2
(en)
|
2021-12-03 |
2026-02-10 |
Amo Groningen B.V. |
Lenses having multi-ring design for vision treatment
|